By Rocky Swift TOKYO (Reuters) - Japan's Shionogi & Co Ltd believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S..
The market disruption triggered by the onset of the COVID-19 pandemic prompted Syneos to abandon those sale deliberations, according to four sources familiar with the discussions. Lucira's home test for flu and COVID-19 gets U.S. FDA nod for OTC use Lucira Health said on Monday the U.S. Food and Drug Administration (FDA) had granted emergency use authorization for its combination diagnostic test for COVID-19 and the flu, making it the first to be available over-the-counter.
The National Institutes of Health said on Wednesday that it had started a clinical trial to evaluate Shionogi s experimental oral antiviral drug to treat COVID-19.